InvestorsHub Logo
Followers 0
Posts 10
Boards Moderated 0
Alias Born 06/28/2013

Re: None

Wednesday, 08/14/2013 1:17:26 PM

Wednesday, August 14, 2013 1:17:26 PM

Post# of 8779
Hi to all...Just received this in response to my email to ESSI...
Hope this answers some of your questions and concerns....

Aug 6, 2013, at 3:47 PM, Edward Withrow

Eaton has recently refiled its Patent Application as part of its pursuit of a US Patent. The Company has signed up a Clinical Trial Facility and are in the process of sending them additional Patient Questionaires. The Company is currently reviewing whether it should largely expand its trial from its current 40 person Study. The FDA recently approved a new non-hormone treatment for relief of hot flshes in menopausal women. The drug is called Brisdelle. Brisdelle was an already approved drug that is prescribed for another indication. Brisdelle had over 1,000 study participants. The Company does not believe that we need that many patients for the homatropine study but we do believe that it would be a good choice to expand the study. We will issue a press release if and when we decide to expand the Study.

Sincerely,

Ted
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.